.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Chubb
Julphar
Colorcon
Fuji
Baxter
US Department of Justice
Harvard Business School
Teva

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,476,279

« Back to Dashboard

Which drugs does patent 8,476,279 protect, and when does it expire?


Patent 8,476,279 protects TRINTELLIX and is included in one NDA.

This patent has seventy patent family members in thirty-six countries.

Summary for Patent: 8,476,279

Title:Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Abstract: The invention provides compounds represented by the general formula I ##STR00001## wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
Inventor(s): Bang-Andersen; Benny (Copenhagen S, DK)
Assignee: H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:13/367,065
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms UsaTRINTELLIXvortioxetine hydrobromideTABLET;ORAL204447-001Sep 30, 2013RXYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
Takeda Pharms UsaTRINTELLIXvortioxetine hydrobromideTABLET;ORAL204447-002Sep 30, 2013RXYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
Takeda Pharms UsaTRINTELLIXvortioxetine hydrobromideTABLET;ORAL204447-003Sep 30, 2013DISCNYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
Takeda Pharms UsaTRINTELLIXvortioxetine hydrobromideTABLET;ORAL204447-004Sep 30, 2013RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,476,279

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2001 01466Oct 04, 2001

Non-Orange Book Patents for Patent: 8,476,279

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,708,280Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
7,138,407Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
9,090,575Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
7,683,053Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
8,110,567Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
7,148,238Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
7,144,884Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,476,279

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Serbia52865► Subscribe
Serbia20120158► Subscribe
Serbia52326► Subscribe
Serbia27704► Subscribe
Portugal1749818► Subscribe
Portugal1436271► Subscribe
Poland210551► Subscribe
Poland209253► Subscribe
Poland368442► Subscribe
New Zealand531556► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Colorcon
Johnson and Johnson
Teva
Argus Health
US Army
Novartis
Moodys
Merck
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot